Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Status:
Completed
Trial end date:
2020-07-28
Target enrollment:
Participant gender:
Summary
The purpose of the study was to provide access to continued treatment for those who
participated in other Astellas sponsored ASP2215 trials that completed the primary analysis
and, had the potential to continue to derive clinical benefit from the treatment with
ASP2215, and who did not meet any of the study discontinuation criteria in the present study.